Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus

Published:2013-02-15 Issue:3 Volume:28 Page:627-638
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Hamann Christine,Rauner Martina,Höhna Yvonne,Bernhardt Ricardo,Mettelsiefen Jan,Goettsch Claudia,Günther Klaus-Peter,Stolina Marina,Han Chun-Ya,Asuncion Franklin J,Ominsky Michael S,Hofbauer Lorenz C

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Reference35 articles.

1. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes;Vestergaard;Calcif Tissue Int.,2009

2. Ensrud KE; Osteoporotic Fractures in Men (MrOs) Study Group. Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study;Petit;J Bone Miner Res.,2010

3. Osteoporosis in patients with diabetes mellitus;Hofbauer;J Bone Miner Res.,2007

4. Bone, sweet bone: osteoporotic fractures in diabetes mellitus;Hamann;Nat Rev Endocrinol.,2012

5. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus;Burghardt;J Clin Endocrinol Metab.,2010

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone Fragility in Diabetes and its Management: A Narrative Review;Drugs;2024-08-05

2. Sclerostin antibody corrects periodontal disease in type 2 diabetic mice;JCI Insight;2024-07-18

3. Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?;European Journal of Endocrinology;2024-06-28

4. Targeting senescent cells to boost bone fracture healing;Journal of Clinical Investigation;2024-06-17

5. Τhe story of sclerostin inhibition: the past, the present, and the future;Hormones;2024-01-03